Latest News by Industry
- Nearly 65 abstracts, including 15 oral presentations on 7 investigational and approved medicines across 8 cancer types, to be presented at the American Society of Hemaotology (ASH) annual congress
NORTH CHICAGO, Ill., Nov. 22, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American Society of Hematology (ASH) annual meeting (December 10-13) in New Orleans, Louisiana.
"Our latest research is driven by our commitment to help improve the health and lives of people living with blood cancers," said Mohamed Zaki, M.D., Ph.D., vice president and global head of oncology development, AbbVie. "The data we are presenting at the ASH annual congress represents progress in our expanding hematology oncology portfolio and the potential to help address more blood cancer patient needs in the future."
At ASH, AbbVie will present the latest data for investigational and approved blood cancer therapies including:
Data presentation details include:
ASH 2022 Abstracts | |
Abstract | Presentation Details All Times in CT |
Ibrutinib | |
Treatment Outcomes After Undetectable MRD With | Session: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations Saturday, December 10, 2022 9:45 a.m. CT Oral Presentation |
Residual Disease Dynamics Among Patients with | Session: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations Saturday, December 10, 2022 10:00 a.m. CT Oral Presentation |
Real-World Comparison of Time to Next Treatment | Session: Outcomes Research—Lymphoid Malignancies: Outcomes in Lymphoma 11:30 a.m. CT Oral Presentation |
Initiating Firstline (1L) Ibrutinib (Ibr) in Chronic | Session: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
Real-World Outcomes With First-Line Ibrutinib (Ibr) | Session: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II Presentation Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Early Adherence and Persistence to First-Line Ibrutinib | Session: Outcomes Research—Lymphoid Malignancies: Poster III Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Real World Treatment Patterns in Patients with Chronic | Session: Outcomes Research—Lymphoid Malignancies: Poster II Session Date/Time: Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Ibrutinib Plus Bendamustine Plus Rituximab and | Session: Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Presentation Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
Effectiveness and Safety of Ibrutinib in Patients with | Session: Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Presentation Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
External Validation of the FLIPI Risk Score Measured at | Session: Outcomes Research—Lymphoid Malignancies: Poster II Presentation Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
FIRE: Overall and Subgroup Results from the Third | Session: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III Presentation Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Use of Ibrutinib in Real Life Settings in France: results | Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III Monday, December 12, 2022 6:00 PM-8:00 PM |
Real-World Outcome of Treatment with Single-Agent | Session: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I Presentation Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
Real-world Outcomes with Ibrutinib in Patients with | Abstract Publication Only |
Venetoclax | |
Long-Term Follow-Up of the Phase 3 VIALE-A Clinical | Session: Acute Myeloid Leukemias: Commercially Available Therapies, Saturday, December 10, 2022 2:30 p.m. CT Oral Presentation |
ELN Risk Stratification Is Not Predictive of Outcomes for | Session: Acute Myeloid Leukemias: Commercially Available Therapies, Sunday, December 11, 2022 4:45 p.m. CT, Oral Presentation |
Multi-Omic Single-Cell Sequencing Reveals Genetic and | Session: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Monday, December 12, 2022 5:00 p.m. CT Oral Presentation |
Comparison of Patients with Newly Diagnosed (ND) | Session: Outcomes Research—Myeloid Malignancies: Poster III Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Real-world Treatment Patterns and Transfusion Burden | Session: Acute Myeloid Leukemias: Commercially Available Therapies, Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
Application of a Validated Composite Comorbidity Score | Session: Acute Myeloid Leukemias: Commercially Available Therapies, Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Clinical Predictors for Relapse Among Patients with | Session: Acute Myeloid Leukemias: Commercially Available Therapies, Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Utilization of antifungal prophylaxis and treatment for | Session: Acute Myeloid Leukemias: Commercially Available Therapies, Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Quality of life in patients with chronic lymphocytic | Abstract Publication Only |
Real World Effectiveness and Safety of Venetoclax In | Abstract Publication Only |
Efficacy and Safety of Treatment Venetoclax | Session: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
The Economic Impact of Treatment Sequencing in the | Session: Health Services and Quality—Lymphoid Malignancies: Real World Monday, December 12, 2022 2:45 - 4:15 p.m. CT Poster Presentation |
Long-Term Host Immune Changes Following Treatment | Session: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Understanding Patient Preferences for Chronic | Session: Health Services and Quality—Lymphoid Malignancies: Poster III Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Residual Disease Dynamics Among Patients with | Session: Chronic Lymphocytic Leukemia: Clinical and Epidemiological Saturday, December 10, 2022 10 a.m. CT Oral Presentation |
Treatment Outcomes After Undetectable MRD With | Session: Outcomes Research—Lymphoid Malignancies: Poster II Saturday, December 10, 2022 9:45 a.m. CT Oral Presentation |
An Updated Safety and Efficacy Analysis of Venetoclax | Session: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Exposure-Response Analysis Supports a Lower Dose of | Session: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Impact of Venetoclax Exposure on Clinical Efficacy and | Session: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
Genomic Landscape of t(11;14) in Multiple Myeloma | Session: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Treatment Patterns and Outcomes in Patients With | Session: Outcomes Research—Myeloid Malignancies: Poster I Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
Real-World Treatment Patterns and Outcomes of | Session: Outcomes Research—Myeloid Malignancies: Poster I Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
A Sensitive Machine Learning-Based Approach to | Session: Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Clinical Genomic Analyses Demonstrate t(11;14) | Session: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
Treatment patterns and overall survival (OS) among | Session: Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Burden of Illness in Patients with Higher-Risk | Session: Outcomes Research—Myeloid Malignancies: Poster III Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
ITCC-101/APAL2020D: A Randomized Phase 3 Trial of | Session: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
Navitoclax | |
The Combination of Navitoclax and Ruxolitinib in JAK | Session: Myeloproliferative Syndromes: Clinical and Epidemiological: Latest Data for Saturday, December 10, 2022 2:00 - 3:30 PM CT; Presentation Time 2:30 PM CT Oral Presentation |
Epcoritamab | |
Evaluation of Epcoritamab and Rituximab Combination | Session: Lymphomas: Translational–Non-Genetic: Poster III Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Phase 1b Trial of Subcutaneous Epcoritamab in | Session: Aggressive Lymphomas: Clinical and Epidemiological: Poster I Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
Phase 2 Trial to Evaluate Safety of Subcutaneous | Session: Aggressive Lymphomas: Clinical and Epidemiological: Poster III Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Phase 3 Trial of Subcutaneous Epcoritamab in | Session: Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Health Care Resource Utilization and Costs of CAR T | Session: Health Services and Quality—Lymphoid Malignancies: Poster I Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
Follicular Lymphoma Treatment Patterns and Outcomes | Session: Outcomes Research—Lymphoid Malignancies: Poster I Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
Indirect Comparisons of the Efficacy of Subcutaneous | Session: Outcomes Research—Lymphoid Malignancies: Poster III Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Subcutaneous Epcoritamab in Novel Combinations with | Abstract Publication Only |
Subcutaneous Epcoritamab + R-Dhax/C in Patients with | Session: Aggressive Lymphomas: Prospective Sunday, December 11, 2022 Session Time: 9:30 - 11:00 a.m. CT; Presentation Time: 10:30 a.m. CT Oral Presentation |
Subcutaneous Epcoritamab with Rituximab + | Session: Mantle Cell, Follicular, and Other Indolent B Cell Sunday, December 11, 2022 Session Time: 4:30 - 6:00 p.m. CT; Presentation Time: 5:00 p.m. CT Oral Presentation |
Subcutaneous Epcoritamab in Combination with | Session: Mantle Cell, Follicular, and Other Indolent B Cell Sunday, December 11, 2022 Session Time: 4:30 - 6:00 p.m. CT; Presentation Time: 5:30 p.m. CT Oral Presentation |
Deep Peripheral T Cell Immune-Profiling in | Session: Lymphomas: Translational–Non-Genetic: Poster II Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Transcriptomic comparison of non-Hodgkin lymphomas | Session: Lymphomas: Translational—Molecular and Genetic: Poster II Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Real-World Outcomes in Patients with Relapsed or | Session: Aggressive Lymphomas: Clinical and Epidemiological: Poster II Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Improvements in Lymphoma Symptoms and Health- | Session: Outcomes Research—Lymphoid Malignancies: Poster II Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Epcoritamab Monotherapy Provides Deep and Durable | Session: Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III Monday, December 12, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
Subcutaneous Epcoritamab in Patients with Richter's | Session: Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Triplet Saturday, December 10, 2022 Session Time: 4:00 - 5:30 p.m. CT; Presentation Time: 5:15 p.m. CT Oral Presentation |
ABBV-319 | |
A First-In-Human Phase I Study of ABBV-319, an | Session: Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
ABBV-383 | |
Dose Escalation and Expansion of ABBV-383 in | Session: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II Sunday, December 11, 2022 6:00 - 8:00 p.m. CT Poster Presentation |
A Phase 1 First-In-Human study of ABBV-383, a BCMA | Session: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I Saturday, December 10, 2022 5:30 - 7:30 p.m. CT Poster Presentation |
The ASH 2022 Annual Meeting abstracts are available here.
Epcoritamab is an investigational anti-CD20 x CD3 bispecific antibody being co-developed by AbbVie and Genmab as part of the companies' broad oncology collaboration. Epcoritamab is not approved by any health authority worldwide at this time. Its safety and efficacy are under evaluation as part of ongoing registrational studies.
Navitoclax is an investigational, oral BCL-XL/BCL-2 inhibitor. Navitoclax is not approved by any health authority worldwide at this time. Its safety and efficacy are under evaluation as part of ongoing registrational studies.
Use of venetoclax in Multiple Myeloma (MM) is not approved by any health authority worldwide at this time. Its safety and efficacy are under evaluation as part of ongoing registrational studies.
A combination of ibrutinib and venetoclax is not approved by any health authority worldwide at this time. Its safety and efficacy are under evaluation as part of ongoing registrational studies.
ABBV-319 and ABBV-383 are not approved by any health authority worldwide at this time. Their safety and efficacy are under evaluation as part of ongoing clinical studies.
About IMBRUVICA®
IMBRUVICA® (ibrutinib) is a once-daily oral medication that is jointly developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. IMBRUVICA® blocks the Bruton's tyrosine kinase (BTK) protein, which is needed by normal and abnormal B cells, including specific cancer cells, to multiply and spread. By blocking BTK, IMBRUVICA® may help move abnormal B cells out of their nourishing environments and inhibits their proliferation.7,8,9
IMBRUVICA® is approved in more than 100 countries and has been used to treat more than 250,000 patients worldwide. There are more than 50 company-sponsored clinical trials, including 18 Phase 3 studies, over 11 years evaluating the efficacy and safety of IMBRUVICA®.
IMBRUVICA® was first approved by the U.S. Food and Drug Administration (FDA) in November 2013, and today is indicated for adult patients in six disease areas, including five hematologic cancers. These include indications to treat adults with CLL/SLL with or without 17p deletion (del17p), adults with Waldenström's macroglobulinemia (WM), adults with previously treated mantle cell lymphoma (MCL)*, adult patients with previously treated marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy*, as well as adult and pediatric patients one year and older with previously treated chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.6
*Accelerated approval was granted for MCL and MZL based on overall response rate. Continued approval for MCL and MZL may be contingent upon verification and description of clinical benefit in confirmatory trials.
For more information, visit www.IMBRUVICA.com.
IMPORTANT SAFETY INFORMATION
Before taking IMBRUVICA®, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.
How should I take IMBRUVICA®?
IMBRUVICA® comes as capsules, tablets, and oral suspension.
What should I avoid while taking IMBRUVICA®?
What are the possible side effects of IMBRUVICA®?
IMBRUVICA® may cause serious side effects, including:
The most common side effects of IMBRUVICA® in adults with B-cell malignancies (MCL, CLL/SLL, WM and MZL) include:
The most common side effects of IMBRUVICA® in adults or children 1 year of age and older with cGVHD include:
Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.
These are not all the possible side effects of IMBRUVICA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of IMBRUVICA®
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it was not prescribed. Do not give IMBRUVICA® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA® that is written for health professionals.
Please see the full Important Product Information.
About VENCLYXTA® (venetoclax)
VENCLYXTA® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTA targets the BCL-2 protein and works to help restore the process of apoptosis.
VENCLYXTA is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the U.S.
Approved Uses of VENCLEXTA
VENCLEXTA is a prescription medicine used:
It is not known if VENCLEXTA is safe and effective in children.
Important Safety Information
What is the most important information I should know about VENCLEXTA?
VENCLEXTA can cause serious side effects, including:
Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS.
You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start treatment and during treatment with VENCLEXTA.
It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you have any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.
Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS.
Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased.
Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you have side effects. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may again check for your risk of TLS and change your dose.
Who should not take VENCLEXTA?
Certain medicines must not be taken when you first start taking VENCLEXTA and while your dose is being slowly increased because of the risk of increased TLS.
Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:
What should I avoid while taking VENCLEXTA?
You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit while you are taking VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.
What are the possible side effects of VENCLEXTA?
VENCLEXTA can cause serious side effects, including:
Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with VENCLEXTA.
The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell counts; low platelet counts; low red blood cell counts; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.
The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine in people with AML include nausea; diarrhea; low platelet count; constipation; low white blood cell count; fever with low white blood cell count; tiredness; vomiting; swelling of arms, legs, hands, or feet; fever; infection in lungs; shortness of breath; bleeding; low red blood cell count; rash; stomach (abdominal) pain; infection in your blood; muscle and joint pain; dizziness; cough; sore throat; and low blood pressure.
VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of VENCLEXTA. Call your doctor for medical advice about side effects.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you cannot afford your medication, contact genentech-access.com/patient/brands/venclexta for assistance.
About Epcoritamab
Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B-cells and induces T cell mediated killing of CD20+ cells.5 CD20 is expressed on B-cells and a clinically validated therapeutic target in many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia.6,7 Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' broad oncology collaboration.
About Navitoclax
Navitoclax is an investigational, oral BCL-XL/BCL-2 inhibitor. The BCL-2 family of proteins are known regulators of the apoptosis pathway.3 Navitoclax is not approved by the U.S. Food and Drug Administration (FDA) or any Health Authority worldwide at this time. Its safety and efficacy are under evaluation as part of ongoing Phase 2 and registrational Phase 3 studies.
AbbVie has an extensive late-stage clinical trial program for investigational navitoclax that is currently enrolling. For more information about enrolling in a clinical trial, please visit us here.
About AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for multiple blood cancers while advancing a dynamic pipeline of investigational therapies across a range of cancer types. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potentially breakthrough medicines. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology and our Blood Cancer Press kit page.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
View original content: https://www.prnewswire.com/news-releases/abbvie-highlights-blood-cancer-data-from-its-growing-oncology-pipeline-at-the-64th-ash-annual-meeting-301685643.html
SOURCE AbbVie